Carlsmed Reports 58% Q1 Revenue Growth and Raises Full-Year Guidance

summarizeSummary

Carlsmed reported strong Q1 2026 revenue growth of 58.2% to $16.1 million, improved gross margins, and raised its full-year revenue guidance, signaling robust performance and increased confidence.

check_boxKey Events

• Strong Q1 Revenue Growth

  Carlsmed reported first-quarter 2026 revenue of $16.1 million, a 58.2% increase compared to $10.2 million in the prior year period.

• Raised Full-Year Revenue Guidance

  The company raised its full-year 2026 revenue guidance to a range of $72 million to $77 million, up from the previous guidance of $70 million to $75 million.

• Improved Gross Margin

  Gross profit for Q1 2026 was $12.4 million, with gross margin improving to 77.1% from 74.9% in Q1 2025.

• Positive Clinical and Product Milestones

  A study published in Global Spine Journal demonstrated a 74% reduction in reoperations for aprevo® personalized lumbar implants. The company also performed the first procedures using the corra™ personalized cervical plating system and aprevo® bi-lateral posterior.

auto_awesomeAnalysis

Carlsmed, Inc. delivered strong first-quarter results, significantly exceeding prior year revenue and raising its full-year guidance. The 58.2% year-over-year revenue growth to $16.1 million, coupled with an improved gross margin of 77.1%, indicates robust operational performance and increasing adoption of its personalized spine surgery solutions. The decision to raise full-year 2026 revenue guidance to $72-$77 million (from $70-$75 million) signals management's increased confidence in continued growth, driven by recent product milestones and positive clinical data. While net loss increased due to higher operating expenses, this is typical for a growth-focused medical technology company investing in research, development, and market expansion. The positive clinical data for aprevo® and the launch of new products further strengthen the company's market position.